(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax TM compared to 2-shot mRNA vaccination series ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
The prospective, epidemiologic School Inner-City Asthma Study (SICAS) evaluated potential biomarkers of inflammation associated with radon exposure among children aged 4 to 13 years with persistent ...
The global coronavirus immunoassay market continues to witness steady growth, reaching USD 3.7 billion in 2021 and is projected to exceed USD 6.9 billion by 2032, expanding at a CAGR of 5.5% during ...